Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

CONVERTER entity

American engineers are probably more familiar with the magnitude of physical entities in U.S. customary units than in SI units. Consequently, errors made in the conversion from one set of units to the other may go undetected. The following six examples will show how to convert the elements in six dimensionless groups. Proper conversions will result in the same numerical value for the dimensionless number. The dimensionless numbers used as examples are the Reynolds, Prandtl, Nusselt, Grashof, Schmidt, and Archimedes numbers. [Pg.43]

Quinoxaline (see Section 2.1.3) and many of its derivatives may be converted into A-alkylquimoxalinium or even A,A -dialkylquinoxalinediium salts by treatment with alkyl halides or the like. Occasionally, when the molecule bears a suitable acidic grouping, it may be possible to deprive the quaternary salt of its gegenion by treatment with a base to form an ylide (in which a carbon atom of the molecule bears the negative charge) or other zwitterionic entity, such as a quinoxaliniumolate. [Pg.129]

Because quinoxalines are often converted into their N-oxides in order to facilitate other reactions, subsequent removal of the oxide entity without untoward effects is quite important. The choice of a reagent for such deoxygenation is frequently governed by the type(s) of passenger group present direct comparisons of several methods have bee presented. " The following classified examples illustrate most of the possibilities available. [Pg.230]

Among the wide and varied types of compounds that are reduced to metals, the oxides are by far the most extensively encountered entities. Metal oxides, in forms amenable to reduction, occur either as principal compounds in ores or can be readily obtained from other compounds that occur in the ores. Many reducing agents are available for converting the oxides to the metal. [Pg.359]

If the structural entities are lamellae, Eq. (8.80) describes an ensemble of perfectly oriented but uncorrelated layers. Inversion of the Lorentz correction yields the scattering curve of the isotropic material I (5) = I (s) / (2ns2). On the other hand, a scattering pattern of highly oriented lamellae or cylinders is readily converted into the ID scattering intensity /, (53) by ID projection onto the fiber direction (p. 136, Eq. (8.56)). The model for the ID intensity, Eq. (8.80), has three parameters Ap, dc, and <7C. For the nonlinear regression it is important to transform to a parameter set with little parameter-parameter correlation Ap, dc, and oc/dc. When applied to raw scattering data, additionally the deviation of the real from the ideal two-phase system must be considered in an extended model function (cf. p. 124). [Pg.179]

The detailed mechanism of inhibition of TEM-2 (class A) enzyme with clavulanate has been established (Scheme 1) [23,24], The inhibition is a consequence of the instability of the acyl enzyme formed between the /1-lactam of clavulanate and the active site Ser-70 of the enzyme. In competition with deacylation, the clavulanate acyl-enzyme complex A undergoes an intramolecular fragmentation. This fragmentation initially provides the new acyl enzyme species B, which is at once capable of further reaction, including tautomeriza-tion to an entity C that is much less chemically reactive to deacylation. This species C then undergoes decarboxylation to give another key intermediate enamine D, which is in equilibrium with imine E. The imine E either forms stable cross-linked vinyl ether F, by interacting with Ser-130 or is converted to the hydrated aldehyde G to complete the inactivation. [Pg.230]

Anti- and syn-12-hydroxyendrin and 12-ketoendrin are more toxic in the rat than endrin itself. The hydroxyendrins ard rapidly converted to the more toxic 12-ketoendrin, and this latter metabolite is most likely the toxic entity of endrin (Bedford et al. 1975a Hutson et al. 1975). [Pg.70]

Concerning the structure, the cyclopropane derivatives 524—526 deviate from the generally observed cycloadducts of cyclic allenes with monoalkenes (see Scheme 6.97 and many examples in Section 6.3). The difference is caused by the different properties of the diradical intermediates that are most likely to result in the first reaction step. In most cases, the allene subunit is converted in that step into an allyl radical moiety that can cyclize only to give a methylenecyclobutane derivative. However, 5 is converted to a tropenyl-radical entity, which can collapse with the radical center of the side-chain to give a methylenecyclobutane or a cyclopropane derivative. Of these alternatives, the formation of the three-membered ring is kinetically favored and hence 524—526 are the products. The structural relationship between both possible product types is made clear in Scheme 6.107 by the example of the reaction between 5 and styrene. [Pg.337]

In pharmaceutical drug analysis a host of organic pharmaceutical substances are invariably converted quantitatively to their corresponding derivatives by virtue of interactions with certain functional entities, namely aldehyde, ketone, amino, carboxyl, phenolic, hydroxyl etc. However, in some cases it may be feasible to obtain uniform substitution products of organic pharmaceutical substances quantitatively, for instance tetraido derivative of phenolphthalein is obtained from the phenolphthalein tablets. It is important to mention here that the number of organic pharmaceutical substances which may be analysed by this method is limited because of two vital reasons, they are ... [Pg.184]

There are several chemical reactions that can be used as an alternative to achieve covalent functionalization of CNTs. Two of them are amidation and/or esterification reactions. Both reactions take advantage of the carboxylic groups sitting on the side-walls and tips of CNTs. In particular, they are converted to acyl chloride groups (-C0-C1) via a reaction with thionyl (SO) or oxalyl chloride before adding an alcohol or an amine. This procedure is very versatile and allows the functionalization of CNTs with different entities such as biomolecules [154-156], polymers [157], and organic compounds [158,159] among others. [Pg.82]

Dixon and Webb present an extensive consideration of activation mechanisms involving the reversible binding of an activator (less often termed an agonist ) to the enzyme. Nonessential activation refers to enzyme-de-pendent processes that can convert substrate(s) to prod-uct(s) in the absence of the activator, albeit at a slower rate. Essential activators are molecular entities that are required by the enzyme in the catalysis of a reaction. In a sense, essential activators are similar to second (or third) substrates, albeit they are not converted to products. An example of an essential activator might be an enzyme that requires the binding of a metal ion for catalysis to proceed. Below are a few cases of essential activation. [Pg.25]

A molecular entity that (a) resembles the substrate (or product) of an enzymic reaction, (b) is chemically unre-active in the absence of the enzyme, (c) binds to the enzyme (d) undergoes activation by the enzyme to yield a chemically reactive species, (e) can be converted to product, and (f) occasionally inactivates the enzyme prior to its release from that protein. [Pg.445]

The binding, reaction, or interception of a reactive molecular entity or transitory intermediate in a reaction pathway to convert the substance to a more stable form and/or remove that substance from the system. Trapping may involve binding or reaction with another molecular entity or involve the alteration of some parameter (e.g., thermal trapping) ... [Pg.687]


See other pages where CONVERTER entity is mentioned: [Pg.294]    [Pg.208]    [Pg.459]    [Pg.157]    [Pg.1363]    [Pg.180]    [Pg.285]    [Pg.114]    [Pg.445]    [Pg.724]    [Pg.217]    [Pg.750]    [Pg.287]    [Pg.323]    [Pg.150]    [Pg.176]    [Pg.562]    [Pg.88]    [Pg.247]    [Pg.336]    [Pg.719]    [Pg.722]    [Pg.342]    [Pg.73]    [Pg.323]    [Pg.67]    [Pg.26]    [Pg.149]    [Pg.165]    [Pg.144]    [Pg.484]    [Pg.176]    [Pg.865]    [Pg.611]    [Pg.847]   
See also in sourсe #XX -- [ Pg.8 ]




SEARCH



Entity

© 2024 chempedia.info